Volume 12, Issue 1 (Winter 2023)                   J Occup Health Epidemiol 2023, 12(1): 12-17 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Heidarzadeh A, Kazemi S, Amini M. Epidemiological Changes in Serum Virus-Specific IgM/IgG Antibody in SARS-CoV-2 Patients in Guilan Province: A Comparative Study. J Occup Health Epidemiol 2023; 12 (1) :12-17
URL: http://johe.rums.ac.ir/article-1-581-en.html

Related article in
Google Scholar

1- Associated Prof., Dept. of Community Medicine, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran , abtinh@gmail.com
2- M.Sc in Epidemiology, Dept. of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
3- M.Sc in Health Education, Deputy of Health، Guilan University of Medical Sciences, Rasht, Iran.
Article history
Received: 2022/04/22
Accepted: 2023/01/25
ePublished: 2023/03/27
Subject: Epidemiology
Abstract:   (432 Views)

Background: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the respiratory disease coronavirus disease 2019 (COVID-19) pandemic. To identify those who have been exposed to the virus and maybe to forecast disease immunity, antibody tests are crucial. We aimed to examine the association between prior COVID-19 infection and antibody levels, including immunoglobulin M (IgM) and immunoglobulin G (IgG) while considering the underlying illnesses in COVID-19 patients in Guilan province.
Materials and Methods: In this descriptive study, 212 individuals with a COVID-19 history participated. Blood samples were taken from people twice. The first time of blood sample collection was in April 2020. The second blood sample collection was around three months after the first time in August 2020. The total immunoglobulins levels specific to SARS-CoV-2 were measured using quantitative enzyme-linked immunosorbent assay (ELISA).
Results: The study included 212 participants, 101 (47.6%) were males, and 111 (52.4%) were women. The age of those who recovered most commonly ranged from 31 to 45 years (31.1%). The most common underlying diseases were Hypertension (31/212), obesity (23/212), cardiovascular disease (17/212), diabetes (17/212), and chronic obstructive pulmonary disease (COPD), respectively. The findings showed that, three months after recovery, the level of IgG remained persistent while the level of IgM had decreased. This revealed that 26/212, or 12.26%, had IgG levels above 1.1.
Conclusion: In individuals who had previously contracted COVID-19, the level of IgG increased over time, whereas the level of IgM decreased.

 
Full-Text [PDF 344 kb]   (220 Downloads)    

References
1. Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020;9(1):45. [DOI] [PMID] [PMCID]
2. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91(1):157-60. [DOI] [PMID] [PMCID]
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. [DOI] [PMID] [PMCID]
4. Kazemi S, Pourgholaminejad A, Saberi A. Stroke Associated with SARS-CoV-2 Infection and its Pathogenesis: A Systematic Review. Basic Clin Neurosci. 2021;12(5):569-86. [DOI] [PMID] [PMCID]
5. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565-74. [DOI] [PMID] [PMCID]
6. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465-9. [DOI] [PMID]
7. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-8. [DOI] [PMID] [PMCID]
8. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020;92(9):1518-24. [DOI] [] []
9. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):940-8. [DOI] [PMID] [PMCID]
10. Qiu X, Xiang Y, Sun J, Wang X, Chen G, Xu X, et al. Dynamic changes of throat swabs RNA and serum antibodies for SARS-CoV-2 and their diagnostic performances in patients with COVID-19. Emerg Microbes Infect. 2020;9(1):1974-83. [DOI] [PMID] [PMCID]
11. Xiao AT, Gao C, Zhang S. Profile of specific antibodies to SARS-CoV-2: The first report. J Infect. 2020;81(1):147-78 [DOI] [PubMed] [PMCID]
12. Zhang X, Lu S, Li H, Wang Y, Lu Z, Liu Z, et al. Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study. Virol Sin. 2020;35(6):820-9. [DIO] [PubMed] [PMCID]
13. Alsayb MA, Alsamiri ADD, Makhdoom HQ, Alwasaidi T, Osman HM, Mahallawi WH. Prolonged humoral and cellular immunity in COVID-19-recovered patients. Saudi J Biol Sci. 2021;28(7):4010-4015. [DOI] [PubMed] [PMCID]
14. Liu A, Wang W, Zhao X, Zhou X, Yang D, Lu M, et al. Disappearance of antibodies to SARS-CoV-2 in a-COVID-19 patient after recovery. Clin Microbiol Infect. 2020;26(12):1703-5. [DOI] [PubMed] [PMCID]
15. Chirathaworn C, Sripramote M, Chalongviriyalert P, Jirajariyavej S, Kiatpanabhikul P, Saiyarin J, et al . SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts, Thailand, April-June 2020. PLoS One. 2020;15(10):e0236905. [DOI] [PubMed] [PMCID]
16. Luo YR, Chakraborty I, Yun C, Wu AHB, Lynch KL. Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Avidity Maturation and Association with Disease Severity. Clin Infect Dis. 2021;73(9):e3095-7. [DOI] [PubMed] [PMCID]
17. Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, et al; Sorbonne Université SARS-CoV-2 Neutralizing Antibodies Study Group; Burrel S, Boutolleau D, Schwartz O, Gorochov G, Calvez V, Marcelin AG. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun. 2021;12(1):844. [DOI] [PubMed] [Google Scholar]
18. Cheng ML, Liu HY, Zhao H, Wang GQ, Zhou C, Zheng J, et al. Longitudinal dynamics of antibody responses in recovered COVID-19 patients. Signal Transduct Target Ther. 2021;6(1):137. [DOI] [PubMed] [Google Scholar]
19. Jiang XL, Wang GL, Zhao XN, Yan FH, Yao L, Kou ZQ, et al. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection. Nat Commun. 2021;12(1):897. [DOI] [PubMed] [Google Scholar]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Occupational Health and Epidemiology

Designed & Developed by : Yektaweb